Sermorelin vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesAnti-Aging & Longevity
SermorelinAnti-Aging & Longevity
Vesugen- Summary
- Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- 10–20 minutes
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–500 mcg
- 10 mg per day
- Frequency
- 5–7 days per week
- Daily for 10–30 days
- Key Benefits
- Increases energy and vitality
- Improves body composition (more muscle, less fat)
- Enhances skin thickness and elasticity
- Strengthens immune system
- Improves sleep quality and REM sleep
- Supports bone density
- Enhances mental clarity and focus
- Safer than exogenous HGH — respects natural feedback loops
- FDA-approved for GH diagnostic use
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Injection site irritation
- Flushing
- Headache
- Dizziness
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —